Ovid Therapeutics (OVID) Resumen de Acciones
Ovid Therapeutics Inc, empresa biofarmacéutica, se dedica al desarrollo de medicamentos de moléculas pequeñas para trastornos cerebrales, incluidas epilepsias y trastornos neurológicos relacionados con convulsiones en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
OVID Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Ovid Therapeutics Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$2.58 |
| Máximo en las últimas 52 semanas | US$3.11 |
| Mínimo de 52 semanas | US$0.53 |
| Beta | 0.23 |
| Cambio en 1 mes | 2.38% |
| Variación en 3 meses | -7.86% |
| Cambio de 1 año | 371.66% |
| Variación en 3 años | -28.13% |
| Variación en 5 años | -29.51% |
| Variación desde la OPV | -78.94% |
Noticias y actualizaciones recientes
OVID: Phase 1 Psychosis Program Will Drive Future Repricing Potential
Analysts have raised the price target for Ovid Therapeutics to $7 from $5, citing updated cash flow models that incorporate expected revenue from Lewy Body Dementia Psychosis and Parkinson's Disease Psychosis indications following the Phase 1 initiation of OV4071. What’s in the News for Ovid Therapeutics On July 6, 2026, Ovid Therapeutics appointed Charles Carter as Chief Financial Officer, following a mutual agreement for former Chief Business and Financial Officer Jeffrey Rona to transition out of his roles.Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
OVID: Index Inclusion And New Psychosis Indications Will Support Bullish Outlook
Analysts have raised their price target on Ovid Therapeutics stock from $5 to $7, citing updated cash flow models that now factor in potential revenue from Lewy Body Dementia Psychosis and Parkinson's Disease Psychosis indications following the start of a Phase 1 study of OV4071. What's in the News for Ovid Therapeutics Ovid Therapeutics added to the S&P Biotechnology Select Industry Index, reflecting inclusion in a widely followed biotech industry benchmark.Recent updates
OVID: Phase 1 Psychosis Program Will Drive Future Repricing Potential
Analysts have raised the price target for Ovid Therapeutics to $7 from $5, citing updated cash flow models that incorporate expected revenue from Lewy Body Dementia Psychosis and Parkinson's Disease Psychosis indications following the Phase 1 initiation of OV4071. What’s in the News for Ovid Therapeutics On July 6, 2026, Ovid Therapeutics appointed Charles Carter as Chief Financial Officer, following a mutual agreement for former Chief Business and Financial Officer Jeffrey Rona to transition out of his roles.Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...OVID: Index Inclusion And New Psychosis Indications Will Support Bullish Outlook
Analysts have raised their price target on Ovid Therapeutics stock from $5 to $7, citing updated cash flow models that now factor in potential revenue from Lewy Body Dementia Psychosis and Parkinson's Disease Psychosis indications following the start of a Phase 1 study of OV4071. What's in the News for Ovid Therapeutics Ovid Therapeutics added to the S&P Biotechnology Select Industry Index, reflecting inclusion in a widely followed biotech industry benchmark.Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines targeting neural hyperexcitability in epilepsy and neuropsychiatric conditions. What are the underlying business or industry changes driving this perspective?Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines for neurological conditions linked to neural hyperexcitability. What are the underlying business or industry changes driving this perspective?Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders
Summary Ovid Therapeutics receives a "Hold" rating as it pivots pipeline focus after soticlestat trial failures in rare epileptic syndromes. OVID reported positive phase 1 results for OV329, a next-generation GABA-AT inhibitor targeting drug-resistant focal onset seizures, with phase 2a trials planned for 2026. Pipeline includes KCC2 activators OV350 (IV) and OV4071 (oral) for neurological and psychiatric disorders, with key data and regulatory milestones expected through 2026. Recent financing extends OVID's cash runway into 2028, but clinical and regulatory risks remain for OVID's early-stage programs. Read the full article on Seeking AlphaOvid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Summary Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome market is expected to reach $1 billion by 2036. Results from the phase 3 Skyway study, using soticlestat for the treatment of patients with Lennox-Gastaut Syndrome, expected by or before September 2024. The global Lennox-Gastaut Syndrome market is expected to reach $1 billion by 2030. Read the full article on Seeking AlphaWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Ovid Therapeutics press release (NASDAQ:OVID): Q2 GAAP EPS of -$0.21 beats by $0.04. Cash, cash equivalents and marketable securities as of June 30, 2022 was $152.4 millionWe Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Ovid Therapeutics Inc.'s...Rentabilidad de los accionistas
| OVID | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 1.6% | 4.9% | 0.09% |
| 1Y | 371.7% | 41.3% | 19.0% |
Rentabilidad vs. Industria: OVID superó a la industria US Biotechs, que obtuvo un rendimiento del 41.3% el año pasado.
Rentabilidad vs. Mercado: OVID superó al mercado US, que obtuvo un rendimiento del 19% el año pasado.
Volatilidad de los precios
| OVID volatility | |
|---|---|
| OVID Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: OVID no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de OVID ha disminuido de 15% a 9% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 23 | Meg Alexander | www.ovidrx.com |
Ovid Therapeutics Inc, empresa biofarmacéutica, se dedica al desarrollo en Estados Unidos de medicamentos de moléculas pequeñas para trastornos cerebrales como epilepsias y trastornos neurológicos relacionados con convulsiones. La empresa está desarrollando el OV329, un inhibidor de GABA-AT que se encuentra en ensayos clínicos de fase 1 para el tratamiento de epilepsias resistentes a fármacos en adultos y niños; y el OV4071, un activador directo del cotransportador 2 de potasio-cloruro por vía oral, el primero en humanos, que se encuentra en ensayos clínicos de fase 1 para el tratamiento de la psicosis asociada a la enfermedad de Parkinson, la demencia por cuerpos de Lewy y la esquizofrenia aguda. Tiene acuerdos de licencia y colaboración con AstraZeneca AB, H. Lundbeck A/S, Northwestern University y Graviton, así como con Marinus Pharmaceuticals, Inc. La empresa se constituyó en 2014 y tiene su sede en Nueva York (Nueva York).
Resumen de fundamentos de Ovid Therapeutics Inc.
| Estadísticas fundamentales de OVID | |
|---|---|
| Capitalización bursátil | US$489.00m |
| Beneficios(TTM) | -US$24.07m |
| Ingresos (TTM) | US$7.12m |
¿Está OVID sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de OVID | |
|---|---|
| Ingresos | US$7.12m |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$7.12m |
| Otros gastos | US$31.19m |
| Beneficios | -US$24.07m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.13 |
| Margen bruto | 100.00% |
| Margen de beneficio neto | -337.99% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado OVID a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/11 06:55 |
| Precio de las acciones al final del día | 2026/08/11 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Ovid Therapeutics Inc. está cubierta por 16 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |